FDA’s CDER Is Fostering Use Of Artificial Intelligence In Drug Development
Executive Summary
Center for Drug Evaluation and Research plans to issue a request for information this year to engage stakeholders on issues related to AI and machine learning. It received 175 AI/ML submissions in 2022, up from 14 in 2020.
You may also be interested in...
US FDA’s Role In Artificial Intelligence/Machine Learning Development Is ‘Convener,’ Califf Says
Speaking at the Consumer Electronics Show, FDA commissioner says agency and industry must work together to understand AI/ML and continuously assess the algorithms for efficacy.
Califf Says US FDA’s Role In Artificial Intelligence/Machine Learning Development Is ‘Convener'
Speaking at the Consumer Electronics Show, FDA commissioner says agency and industry must work together to understand AI/ML and continuously assess the algorithms for efficacy.
US FDA’s Role In Artificial Intelligence/Machine Learning Development Is ‘Convener,’ Califf Says
Speaking at the Consumer Electronics Show, FDA commissioner says agency and industry must work together to understand AI/ML and continuously assess the algorithms for efficacy.